Fibronectin: How its aberrant expression in tumors may improve therapeutic targeting

Journal of Cancer

Volumn 8, Issue 4, 2017, Pages 674-682

  Wang, Jennifer Peyling ^a   Hielscher, Abigail ^a  

^a PHILADELPHIA COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

Author keywords

Extracellular matrix; Fibronectin; Integrins; Metastasis; Therapy resistance; Tumorigenesis

Indexed keywords

CELL RECEPTOR; FIBRONECTIN; LIGAND;

CANCER PROGNOSIS; CANCER RESISTANCE; CARCINOGENESIS; CELL INTERACTION; HUMAN; INTRACELLULAR SIGNALING; METASTASIS; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVIEW; TUMOR GROWTH; TUMOR INVASION;

EID: 85013960698     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.16901     Document Type: Review

References (50)

1. Jarvelainen H, Sainio A, Koulu M, Wight TN, Penttinen R. Extracellular matrix molecules: potential targets in pharmacotherapy. Pharmacological reviews. 2009; 61: 198-223.
2. Pankov R, Yamada KM. Fibronectin at a glance. Journal of cell science. 2002; 115: 3861-3.
3. Mierke CT, Frey B, Fellner M, Herrmann M, Fabry B. Integrin alpha5beta1 facilitates cancer cell invasion through enhanced contractile forces. Journal of cell science. 2011; 124: 369-83.
4. Mitra AK, Sawada K, Tiwari P, Mui K, Gwin K, Lengyel E. Ligand-independent activation of c-Met by fibronectin and alpha(5)beta(1)-integrin regulates ovarian cancer invasion and metastasis. Oncogene. 2011; 30: 1566-76.
5. Nam JM, Onodera Y, Bissell MJ, Park CC. Breast cancer cells in three-dimensional culture display an enhanced radioresponse after coordinate targeting of integrin alpha5beta1 and fibronectin. Cancer research. 2010; 70: 5238-48.
6. Lou X, Han X, Jin C, Tian W, Yu W, Ding D, et al. SOX2 targets fibronectin 1 to promote cell migration and invasion in ovarian cancer: new molecular leads for therapeutic intervention. Omics: a journal of integrative biology. 2013; 17: 510-8.
7. Wei PL, Kuo LJ, Huang MT, Ting WC, Ho YS, Wang W, et al. Nicotine enhances colon cancer cell migration by induction of fibronectin. Annals of surgical oncology. 2011; 18: 1782-90.
8. Kenny HA, Chiang CY, White EA, Schryver EM, Habis M, Romero IL, et al. Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion. The Journal of clinical investigation. 2014; 124: 4614-28.
9. Knowles LM, Gurski LA, Engel C, Gnarra JR, Maranchie JK, Pilch J. Integrin alphavbeta3 and fibronectin upregulate Slug in cancer cells to promote clot invasion and metastasis. Cancer research. 2013; 73: 6175-84.
10. Eke I, Storch K, Krause M, Cordes N. Cetuximab attenuates its cytotoxic and radiosensitizing potential by inducing fibronectin biosynthesis. Cancer research. 2013; 73: 5869-79.
11. Murphy LC, Seekallu SV, Watson PH. Clinical significance of estrogen receptor phosphorylation. Endocrine-related cancer. 2011; 18: R1-14.
12. Pontiggia O, Sampayo R, Raffo D, Motter A, Xu R, Bissell MJ, et al. The tumor microenvironment modulates tamoxifen resistance in breast cancer: a role for soluble stromal factors and fibronectin through beta1 integrin. Breast cancer research and treatment. 2012; 133: 459-71.
13. Williams CM, Engler AJ, Slone RD, Galante LL, Schwarzbauer JE. Fibronectin expression modulates mammary epithelial cell proliferation during acinar differentiation. Cancer research. 2008; 68: 3185-92.
14. Han SW, Roman J. Fibronectin induces cell proliferation and inhibits apoptosis in human bronchial epithelial cells: pro-oncogenic effects mediated by PI3-kinase and NF-kappa B. Oncogene. 2006; 25: 4341-9.
15. Huang W, Chiquet-Ehrismann R, Moyano JV, Garcia-Pardo A, Orend G. Interference of tenascin-C with syndecan-4 binding to fibronectin blocks cell adhesion and stimulates tumor cell proliferation. Cancer research. 2001; 61: 8586-94.
16. Teng Y, Qiu J., Zheng Y., et al. Effects of type I collagen and fibronectin on regulation of breast cancer cell biological and biochemical characteristics. Journal of Medical and Biological Engineering. 2014; 34: 62-8
17. Sengupta S, Nandi S, Hindi ES, Wainwright DA, Han Y, Lesniak MS. Short hairpin RNA-mediated fibronectin knockdown delays tumor growth in a mouse glioma model. Neoplasia. 2010; 12: 837-47.
18. Rybak JN, Roesli C, Kaspar M, Villa A, Neri D. The extra-domain A of fibronectin is a vascular marker of solid tumors and metastases. Cancer research. 2007; 67: 10948-57.
19. Xiang L, Xie G, Ou J, Wei X, Pan F, Liang H. The extra domain A of fibronectin increases VEGF-C expression in colorectal carcinoma involving the PI3K/AKT signaling pathway. PloS one. 2012; 7: e35378.
20. Ou J, Deng J, Wei X, Xie G, Zhou R, Yu L, et al. Fibronectin extra domain A (EDA) sustains CD133(+)/CD44(+) subpopulation of colorectal cancer cells. Stem cell research. 2013; 11: 820-33.
21. Rossnagl S, Altrock E, Sens C, Kraft S, Rau K, Milsom MD, et al. EDA-Fibronectin Originating from Osteoblasts Inhibits the Immune Response against Cancer. PLoS biology. 2016; 14: e1002562.
22. Khan ZA, Chan BM, Uniyal S, Barbin YP, Farhangkhoee H, Chen S, et al. EDB fibronectin and angiogenesis-a novel mechanistic pathway. Angiogenesis. 2005; 8: 183-96.
23. Midulla M, Verma R, Pignatelli M, Ritter MA, Courtenay-Luck NS, George AJ. Source of oncofetal ED-B-containing fibronectin: implications of production by both tumor and endothelial cells. Cancer research. 2000; 60: 164-9.
24. Han Z, Zhou Z, Shi X, Wang J, Wu X, Sun D, et al. EDB Fibronectin Specific Peptide for Prostate Cancer Targeting. Bioconjugate chemistry. 2015; 26: 830-8.
25. Neil JR, Johnson KM, Nemenoff RA, Schiemann WP. Cox-2 inactivates Smad signaling and enhances EMT stimulated by TGF-beta through a PGE2-dependent mechanisms. Carcinogenesis. 2008; 29: 2227-35.
26. Sawada K, Mitra AK, Radjabi AR, Bhaskar V, Kistner EO, Tretiakova M, et al. Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target. Cancer research. 2008; 68: 2329-39.
27. Malik G, Knowles LM, Dhir R, Xu S, Yang S, Ruoslahti E, et al. Plasma fibronectin promotes lung metastasis by contributions to fibrin clots and tumor cell invasion. Cancer research. 2010; 70: 4327-34.
28. Balanis N, Wendt MK, Schiemann BJ, Wang Z, Schiemann WP, Carlin CR. Epithelial to mesenchymal transition promotes breast cancer progression via a fibronectin-dependent STAT3 signaling pathway. The Journal of biological chemistry. 2013; 288: 17954-67.
29. Meng XN, Jin Y, Yu Y, Bai J, Liu GY, Zhu J, et al. Characterisation of fibronectin-mediated FAK signalling pathways in lung cancer cell migration and invasion. British journal of cancer. 2009; 101: 327-34.
30. Yuan J, Liu M, Yang L, Tu G, Zhu Q, Chen M, et al. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and beta1-integrin signaling pathway in tumor cells. Breast cancer research: BCR. 2015; 17: 69.
31. Rintoul RC, Sethi T. Extracellular matrix regulation of drug resistance in small-cell lung cancer. Clinical science. 2002; 102: 417-24.
32. Spangenberg C, Lausch EU, Trost TM, Prawitt D, May A, Keppler R, et al. ERBB2-mediated transcriptional up-regulation of the alpha5beta1 integrin fibronectin receptor promotes tumor cell survival under adverse conditions. Cancer research. 2006; 66: 3715-25.
33. Carbonell WS, DeLay M, Jahangiri A, Park CC, Aghi MK. beta1 integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumab-resistant glioblastoma. Cancer research. 2013; 73: 3145-54.
34. Lu P, Weaver VM, Werb Z. The extracellular matrix: a dynamic niche in cancer progression. The Journal of cell biology. 2012; 196: 395-406.
35. Provenzano PP, Inman DR, Eliceiri KW, Keely PJ. Matrix density-induced mechanoregulation of breast cell phenotype, signaling and gene expression through a FAK-ERK linkage. Oncogene. 2009; 28: 4326-43.
36. Ilic D, Kovacic B, Johkura K, Schlaepfer DD, Tomasevic N, Han Q, et al. FAK promotes organization of fibronectin matrix and fibrillar adhesions. Journal of cell science. 2004; 117: 177-87.
37. Francois RA, Maeng K, Nawab A, Kaye FJ, Hochwald SN, Zajac-Kaye M. Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors. Journal of the National Cancer Institute. 2015; 107.
38. Csiszar K. Lysyl oxidases: a novel multifunctional amine oxidase family. Progress in nucleic acid research and molecular biology. 2001; 70: 1-32.
39. Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT, et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell. 2009; 139: 891-906.
40. Adam O, Theobald K, Lavall D, Grube M, Kroemer HK, Ameling S, et al. Increased lysyl oxidase expression and collagen cross-linking during atrial fibrillation. Journal of molecular and cellular cardiology. 2011; 50: 678-85.
41. Tomasini-Johansson BR, Kaufman NR, Ensenberger MG, Ozeri V, Hanski E, Mosher DF. A 49-residue peptide from adhesin F1 of Streptococcus pyogenes inhibits fibronectin matrix assembly. The Journal of biological chemistry. 2001; 276: 23430-9.
42. Chiang HY, Korshunov VA, Serour A, Shi F, Sottile J. Fibronectin is an important regulator of flow-induced vascular remodeling. Arteriosclerosis, thrombosis, and vascular biology. 2009; 29: 1074-9.
43. Hielscher A, Ellis K, Qiu C, Porterfield J, Gerecht S. Fibronectin Deposition Participates in Extracellular Matrix Assembly and Vascular Morphogenesis. PloS one. 2016; 11: e0147600.
44. Thundimadathil J. Cancer treatment using peptides: current therapies and future prospects. Journal of amino acids. 2012; 2012: 967347.
45. de Fougerolles AR. Delivery vehicles for small interfering RNA in vivo. Human gene therapy. 2008; 19: 125-32.
46. Foerg C, Ziegler U, Fernandez-Carneado J, Giralt E, Merkle HP. Differentiation restricted endocytosis of cell penetrating peptides in MDCK cells corresponds with activities of Rho-GTPases. Pharmaceutical research. 2007; 24: 628-42.
47. Endoh T, Ohtsuki T. Cellular siRNA delivery using cell-penetrating peptides modified for endosomal escape. Advanced drug delivery reviews. 2009; 61: 704-9.
48. Kumar P, Wu H, McBride JL, Jung KE, Kim MH, Davidson BL, et al. Transvascular delivery of small interfering RNA to the central nervous system. Nature. 2007; 448: 39-43.
49. Jefferson A, Cadet VE, Hielscher A. The mechanisms of genetically modified vaccinia viruses for the treatment of cancer. Critical reviews in oncology/hematology. 2015; 95: 407-16.
50. Lopez MV, Rivera AA, Viale DL, Benedetti L, Cuneo N, Kimball KJ, et al. A tumor-stroma targeted oncolytic adenovirus replicated in human ovary cancer samples and inhibited growth of disseminated solid tumors in mice. Molecular therapy: the journal of the American Society of Gene Therapy. 2012; 20: 2222-33.